In 2002, the first long-acting muscarinic antagonist, tiotropium bromide (Spiriva®), was
launched as a once-daily bronchodilating agent for the treatment of chronic obstructive …

Background Many patients with asthma remain symptomatic despite treatment with inhaled
corticosteroids (ICS) with or without long-acting β 2-agonists (LABAs). Tiotropium add-on to …

Inhaled antimuscarinics, often called anticholinergics in clinical medicine, are established as
first line bronchodilators in COPD. Tiotropium has been developed as a new generation …

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled
corticosteroids (ICS) plus one or more controller therapies in adolescents with severe …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation caused by persistent inflammatory processes in the airways. An increased …

Background: Patients with chronic obstructive pulmonary disease (COPD) who were naive
to anticholinergics before the TIOtropium Safety and Performance In Respimat (TIOSPIR) …

Several current guidelines/strategies outline a treatment approach to asthma, which
primarily consider the goals of improving lung function and quality of life and reducing …

Background Tiotropium is a new anticholinergic therapy for chronic obstructive pulmonary
disease (COPD) that differs from ipratropium by its functional relative selectivity for …

The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary
disease (COPD) is well established. More recently, the potential for long-acting muscarinic …

Background and purpose Long-acting muscarinic antagonists (LAMAs) have been
recommended for the treatment of chronic obstructive pulmonary disease and (more …